Sudhakar Katakam

Array ( [id] => 18391383 [patent_doc_number] => 20230159601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => PHARMACEUTICAL COMPOSITION FOR LOWERING BLOOD CHOLESTEROL, PREVENTING OR TREATING CARDIOVASCULAR DISEASES AND REDUCING INFLAMMATION [patent_app_type] => utility [patent_app_number] => 17/905461 [patent_app_country] => US [patent_app_date] => 2020-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13540 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17625798 [patent_doc_number] => 20220160813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => INHIBITORS FOR PROLIFERATING CELL NUCLEAR ANTIGEN AND USES [patent_app_type] => utility [patent_app_number] => 16/991534 [patent_app_country] => US [patent_app_date] => 2020-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20663 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 244 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16991534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16483962 [patent_doc_number] => 20200377563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => NOVEL SPECIFIC-BINDING POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/987218 [patent_app_country] => US [patent_app_date] => 2020-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16987218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17526815 [patent_doc_number] => 11299486 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-12 [patent_title] => Benzazole compounds and methods for making and using the compounds [patent_app_type] => utility [patent_app_number] => 16/928413 [patent_app_country] => US [patent_app_date] => 2020-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19915 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 165 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16928413 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17805871 [patent_doc_number] => 20220257706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) LIGANDS [patent_app_type] => utility [patent_app_number] => 17/625314 [patent_app_country] => US [patent_app_date] => 2020-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13950 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17625314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17805871 [patent_doc_number] => 20220257706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) LIGANDS [patent_app_type] => utility [patent_app_number] => 17/625314 [patent_app_country] => US [patent_app_date] => 2020-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13950 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17625314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902721 [patent_doc_number] => 20240018206 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => AN INTERLEUKIN-1 RECEPTOR ANTAGONIST AND A FUSION PROTEIN CONTAINING THE SAME [patent_app_type] => utility [patent_app_number] => 17/927625 [patent_app_country] => US [patent_app_date] => 2020-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6293 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902721 [patent_doc_number] => 20240018206 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => AN INTERLEUKIN-1 RECEPTOR ANTAGONIST AND A FUSION PROTEIN CONTAINING THE SAME [patent_app_type] => utility [patent_app_number] => 17/927625 [patent_app_country] => US [patent_app_date] => 2020-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6293 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17882727 [patent_doc_number] => 20220298204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => SYNTHESIS OF A-AMANITIN AND ITS DERIVATIVES [patent_app_type] => utility [patent_app_number] => 17/624849 [patent_app_country] => US [patent_app_date] => 2020-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14305 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17624849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16581483 [patent_doc_number] => 20210015885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => SMALL MOLECULE RAS INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/919031 [patent_app_country] => US [patent_app_date] => 2020-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19860 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16919031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16540987 [patent_doc_number] => 20200407400 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => NOVEL THETA DEFENSIN ANALOGS [patent_app_type] => utility [patent_app_number] => 16/914038 [patent_app_country] => US [patent_app_date] => 2020-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16914038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17975526 [patent_doc_number] => 11492374 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-08 [patent_title] => Peptides for treatment of medical disorders [patent_app_type] => utility [patent_app_number] => 16/911701 [patent_app_country] => US [patent_app_date] => 2020-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 19481 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16911701 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16555786 [patent_doc_number] => 20210000934 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => POLYMER ADJUVANT [patent_app_type] => utility [patent_app_number] => 16/907912 [patent_app_country] => US [patent_app_date] => 2020-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20419 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16907912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16569145 [patent_doc_number] => 20210008151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => FORMULATIONS CONTAINING A SOMATOSTATIN RECEPTOR AGONIST [patent_app_type] => utility [patent_app_number] => 16/908055 [patent_app_country] => US [patent_app_date] => 2020-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19585 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16908055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16525259 [patent_doc_number] => 20200399339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => PROCESS FOR THE PREPARATION OF HIGH PURITY GLUCAGON [patent_app_type] => utility [patent_app_number] => 16/905474 [patent_app_country] => US [patent_app_date] => 2020-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5265 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16905474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343887 [patent_doc_number] => 20200308537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => CELL CULTURE MEDIUM COMPRISING SMALL PEPTIDES [patent_app_type] => utility [patent_app_number] => 16/903242 [patent_app_country] => US [patent_app_date] => 2020-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16903242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16341696 [patent_doc_number] => 20200306346 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID [patent_app_type] => utility [patent_app_number] => 16/902153 [patent_app_country] => US [patent_app_date] => 2020-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63926 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 855 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16902153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17641939 [patent_doc_number] => 20220169677 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => NRP-1 BINDING INHIBITORY PEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/618233 [patent_app_country] => US [patent_app_date] => 2020-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11737 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17618233 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16469532 [patent_doc_number] => 20200371069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => PURIFICATION OF GLUCAGON-LIKE PEPTIDE 1 ANALOGS [patent_app_type] => utility [patent_app_number] => 16/893906 [patent_app_country] => US [patent_app_date] => 2020-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12183 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16893906 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807440 [patent_doc_number] => 20220259275 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => NOVEL PEPTOID BLOCKING O-GlcNAcylated NF-kappaB c-Rel [patent_app_type] => utility [patent_app_number] => 17/595960 [patent_app_country] => US [patent_app_date] => 2020-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5397 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17595960 [rel_patent_id] =>[rel_patent_doc_number] =>)